Pharmacy

Your Article Summary

See Latest Articles

Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease
Journal of Clinical Pharmacy and Therapeutics, 06/18/09

Small DS et al. - Moderate hepatic impairment appears to have no effect on exposure to prasugrel's active metabolite. Furthermore, MPA results suggest that moderate hepatic impairment has little or no effect on platelet aggregation relative to healthy controls. Overall, these results suggest that a dose adjustment would not be required in moderately hepatically impaired patients taking prasugrel.

Today in Pharmacokinetics...keeping you current

Receive free subspecialty "5-minute updates" via email

Evaluation of Anti-HBs Serum Levels and Pharmacokinetic Profile After Intravenous Administration of Niuliva, a New Hepatitis B Immunoglobulin, Following Liver Transplantation
Transplantation Proceedings, 12/16/09

Which drug is effective and safe for acute malaria in pregnancy? Reviewing the evidence
Drug Development Research, 12/16/09

Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer
The Journal of Nuclear Medicine, 12/16/09

 See all of Pharmacokinetics

Today in Stomach/GI...keeping you current

Receive free subspecialty "5-minute updates" via email

The efficacy and safety of telaprevir ? a new protease inhibitor against hepatitis C virus
Expert Opinion on Investigational Drugs, 12/16/09

Clinically-Staged T3N0 Rectal Cancer: Is Preoperative Chemoradiotherapy the Optimal Treatment
Annals of Surgical Oncology, 12/16/09

Patient attitudes towards and experiences with an intervention programme to reduce chronic acid-suppressing drug intake in primary care
The European Journal of General Practice, 12/16/09

 See all of Stomach/GI